Adjuvant therapy with Imatinib for gastrointestinal stromal tumors has been evaluated in multiple trials. Patients who were identified as intermediate risk had a clinical course that was similar to the low-risk group, suggesting that only high-risk patients would likely benefit from adjuvant therapy. As patients labeled as very low, low, or intermediate risk have minimal benefit from adjuvant therapy it is usually not offered in this setting. The impact of adjuvant therapy on the quality of life of patients with breast cancer in Iraq. The aim of this study was to evaluate or to assess the impact of adjuvant therapy on quality of life in patients with breast cancer, and to find out the differences in the quality of life between patients receiving chemotherapy and radiation therapy.
The peer review process is highly appreciated by researchers globally. Editorial Board Members and Reviewers actively participate in the review process within 21 days and ensure the quality of the manuscripts. OMICS Group has more than 700+ peer-reviewed journals which are publishing quality articles and conduct around 3000+ International Scientific Conferences worldwide.
Last date updated on October, 2020